Vlado Perkovic

Level 5, 1 King St
Newtown, NSW 2042, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 420 publications

Efficacy and safety of canagliflozin are consistent across polypharmacy burden in CKD: the CREDENCE trial.

Efficacy and safety of canagliflozin are consistent across polypharmacy burden in CKD: the CREDENCE trial.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Published: September 04, 2026

Inflammation as a therapeutic target to improve kidney and cardiovascular outcomes.

Inflammation as a therapeutic target to improve kidney and cardiovascular outcomes.

Journal: Nature reviews. Nephrology
Published: August 06, 2026

Design and baseline characteristics of the ZENITH high proteinuria trial testing zibotentan/dapagliflozin efficacy in CKD.

Design and baseline characteristics of the ZENITH high proteinuria trial testing zibotentan/dapagliflozin efficacy in CKD.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Published: August 04, 2026

Finerenone in hypertensive non-diabetic chronic kidney disease: a FIND-CKD subgroup analysis.

Finerenone in hypertensive non-diabetic chronic kidney disease: a FIND-CKD subgroup analysis.

Journal: European heart journal
Published: July 24, 2026

Sex disparities in receiving evidence-based medications in patients with CKD.

Sex disparities in receiving evidence-based medications in patients with CKD.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Published: June 19, 2026

Finerenone in Patients With Chronic Kidney Disease Due to Glomerular Diseases: A Randomized Clinical Trial.

Finerenone in Patients With Chronic Kidney Disease Due to Glomerular Diseases: A Randomized Clinical Trial.

Journal: JAMA
Published: June 05, 2026

Finerenone in Persons with Chronic Kidney Disease without Diabetes.

Finerenone in Persons with Chronic Kidney Disease without Diabetes.

Journal: The New England journal of medicine
Published: June 05, 2026

Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease: The TRACK Randomized Clinical Trial.

Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease: The TRACK Randomized Clinical Trial.

Journal: JAMA
Published: June 04, 2026

Response to Comment on Rossing et al. Nuances in Interpretation: Assessing the Interaction Between Semaglutide and MRAs in the FLOW Trial.

Response to Comment on Rossing et al. Nuances in Interpretation: Assessing the Interaction Between Semaglutide and MRAs in the FLOW Trial.

Journal: Diabetes care
Published: May 20, 2026

Telitacicept for IgA Nephropathy - Interim Analysis of a Phase 3 Trial.

Telitacicept for IgA Nephropathy - Interim Analysis of a Phase 3 Trial.

Journal: The New England journal of medicine
Published: May 13, 2026

Efficacy and safety of finerenone in patients with chronic kidney disease: an individual participant data pooled analysis (INFINITY).

Efficacy and safety of finerenone in patients with chronic kidney disease: an individual participant data pooled analysis (INFINITY).

Journal: Lancet (London, England)
Published: April 23, 2026

Iptacopan in IgA Nephropathy - Final 24-Month Data.

Iptacopan in IgA Nephropathy - Final 24-Month Data.

Journal: The New England journal of medicine
Published: March 30, 2026
Showing 1-12 of 420

Last Updated: 09/26/2026